MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s12876-022-02284-z

Медицинская библиотека · BMC gastroenterology · 2022

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.

Komaki Yuri, Ozono Yoshinori, Nakamura Kenichi, Iwakiri Hisayoshi, Hasuike Satoru, Sueta Mitsue, Miike Tadashi, Yamamoto Shojiro, Uto Hirofumi, Kusumoto Kazunori, Ochiai Toshimasa, Kato Junya, Komada Naoto, Kuroki Kazuo, Eto Toshiharu, Shigehira Masafumi, Hirono Shuichi, Nagata Kenji, Kawakami Hiroshi

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy and safety of glecaprevir and pibrentasvir (G/P) treatment in Japanese patients with HCV infection aged ≥ 75 years.

METHODS

This multicenter, retrospective study included 271 Japanese patients with HCV infection from 12 centers in Miyazaki Prefecture, Japan. Demographic, clinical, virological, and adverse events (AEs) data obtained during and after G/P treatment were collected from medical records. The patients were divided into two groups: younger (n = 199, aged < 75 years) and older (n = 72, aged ≥ 75 years). Virological data and AEs were analyzed according to the age group.

RESULTS

In intention-to-treat (ITT) and per-protocol analyses, the overall sustained virological response 12 (SVR12) rates were 93% and 98.8%, respectively. Two patients in the older group and 14 patients in the younger group dropped out before SVR12 assessment. Although patients in the older group tended to have liver cirrhosis, 95.8% in the older group and 92% in the younger group achieved SVR12 in the ITT analysis (P = 0.404). In total, 48 (17.7%) patients experienced treatment-related AEs. Common AEs during treatment included pruritus, headache, and fatigue. The AEs were not significantly different between the two groups.

CONCLUSIONS

Compared with younger patients, older patients showed similar virological response and tolerance to G/P treatment.

Для цитирования: Komaki Yuri, Ozono Yoshinori, Nakamura Kenichi, Iwakiri Hisayoshi, Hasuike Satoru, Sueta Mitsue, Miike Tadashi, Yamamoto Shojiro, Uto Hirofumi, Kusumoto Kazunori, Ochiai Toshimasa, Kato Junya, Komada Naoto, Kuroki Kazuo, Eto Toshiharu, Shigehira Masafumi, Hirono Shuichi, Nagata Kenji, Kawakami Hiroshi. Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.. BMC gastroenterology. 2022. DOI: 10.1186/s12876-022-02284-z.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.